NEWYou can now listen to Fox News articles!

With new agreements from President Donald Trump promising lower prices on popular weight-loss drugs, the use of GLP-1 medications such as Ozempic and Mounjaro could soon surge even higher — a trend already spreading unevenly across the U.S., with some states seeing greater uptick than others.

Based on insurance claims data from Purple Lab, a Pennsylvania health analytics company, a 2024 report published by GLP-1 Newsroom broke down the estimated number of weight-loss and diabetes drug prescriptions per state.

The prescription records came from both commercial and government insurers, and they don’t include people who paid cash, used telehealth providers, used compounded versions or were uninsured — which means the actual numbers are likely hig

See Full Page